BioRestorative Therapies (BRTX) Shares Outstanding (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Shares Outstanding (Entity) came in at $8.9 million in Q4 2025, up 28.27% YoY from $6.9 million in Q4 2024, and up 11.26% on a QoQ basis from $8.0 million in Q3 2025.
BioRestorative Therapies (BRTX) Shares Outstanding (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Shares Outstanding (Entity) data on file, last reported at $8.9 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 28.27% year-over-year to $8.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.9 million (up 28.27% YoY) and the FY2025 annual result came in at $8.9 million, up 28.27% from the prior year.
- Shares Outstanding (Entity) grew to $8.9 million in Q4 2025, from $8.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $8.9 million in Q4 2025 to a low of $793978.0 in Q1 2021.
- A 5-year average of $4.8 million and a median of $4.3 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) surged 357.41% — and 2023, when it rose 3.74%.
- Tracing BRTX's Shares Outstanding (Entity) over 5 years: stood at $1.2 million in 2021, then jumped by 209.64% to $3.7 million in 2022, then advanced by 27.98% to $4.7 million in 2023, then soared by 47.02% to $6.9 million in 2024, then advanced by 28.27% to $8.9 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $8.9 million (Q4 2025), $8.0 million (Q3 2025), and $8.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | 8.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.99 Mn |
| Sep 30, 2025 | 9.12 Mn |
| Jun 30, 2025 | 8.74 Mn |
| Mar 31, 2025 | 8.36 Mn |
| Dec 31, 2024 | 7.76 Mn |
| Sep 30, 2024 | 8.12 Mn |
| Jun 30, 2024 | 8.12 Mn |
| Mar 31, 2024 | 6.67 Mn |
| Dec 31, 2023 | 4.22 Mn |
| Sep 30, 2023 | 4.57 Mn |
| Jun 30, 2023 | 3.89 Mn |
| Mar 31, 2023 | 3.72 Mn |
| Dec 31, 2022 | 3.62 Mn |
| Sep 30, 2022 | 3.64 Mn |
| Jun 30, 2022 | 3.64 Mn |
| Mar 31, 2022 | 3.52 Mn |
| Dec 31, 2021 | 1.19 Mn |
| Sep 30, 2021 | 838,689.00 |
| Jun 30, 2021 | 795,877.00 |
| Mar 31, 2021 | 729,930.00 |